Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.

@article{Molina2008EvaluationOL,
  title={Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.},
  author={J. Molina and Scott H. Kaufmann and Joel M. Reid and Stephen D. Rubin and Marina G{\'a}lvez-Peralta and Robert Friedman and Karen S. Flatten and Kevin Koch and Tona M Gilmer and Robert J. Mullin and Roxanne C. Jewell and Sara J. Felten and Sumithra J. Mandrekar and Araba A. Adjei and Charles Erlichman},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2008},
  volume={14 23},
  pages={7900-8}
}
PURPOSE Topotecan resistance can result from drug efflux by P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) as well as survival signals initiated by epidermal growth factor receptor family members. The present studies were done to determine the effect of combining topotecan and the dual epidermal growth factor receptor/HER2 inhibitor lapatinib in tissue culture, a murine xenograft model, and a phase I clinical trial. EXPERIMENTAL DESIGN The effects of lapatinib on topotecan… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society • 2012
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…